What it's for (Indications)
- Loteprednol etabonate + tobramycin ophthalmic suspension is indicated for the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
- Such conditions may include palpebral and bulbar conjunctivitis, keratitis, and anterior uveitis, as well as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain a diminution in edema and inflammation.
- It is also indicated for chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies, where the combination therapy addresses both inflammation and potential bacterial contamination.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The typical dosage for loteprednol etabonate + tobramycin ophthalmic suspension is to instill one drop into the conjunctival sac of the affected eye(s) four times daily. The duration of treatment should generally not exceed 14 days. The frequency of instillation may be adjusted by a physician based on the severity of the inflammation and infection, with a potential for initial higher frequency in acute severe cases, followed by tapering. Patients should be advised to shake the bottle well before each use to ensure uniform suspension. Care should be taken to avoid contamination of the dropper tip with ocular or periocular tissues. |
Safety & Warnings
Common Side Effects
- The most common ocular adverse reactions reported with loteprednol etabonate + tobramycin ophthalmic suspension include temporary blurred vision, ocular irritation, burning or stinging upon instillation, ocular pain, foreign body sensation, and pruritus.
- Less common but more serious ocular effects associated with corticosteroid use include elevated intraocular pressure (IOP) possibly leading to glaucoma, posterior subcapsular cataract formation, optic nerve damage, corneal thinning, and perforation.
- Secondary ocular infections (bacterial, fungal, viral) may also occur.
- Hypersensitivity reactions (e.
- g.
- , lid edema, erythema, conjunctival injection) have been reported with tobramycin.
- Systemic absorption is generally minimal, but systemic side effects are theoretically possible with prolonged high-dose use.
- If adverse reactions persist or worsen, patients should consult their ophthalmologist.
Serious Warnings
- Black Box Warning: **Serious Warnings:** Prolonged use of ophthalmic corticosteroids, including loteprednol etabonate, may lead to several serious ocular complications. These include elevated intraocular pressure (IOP) which can progress to glaucoma with optic nerve damage, visual field defects, and posterior subcapsular cataract formation. Regular monitoring of intraocular pressure is essential, especially in patients receiving therapy for extended periods (e.g., more than 10 days) and in pediatric patients. The prolonged use of loteprednol etabonate + tobramycin may also suppress the host immune response, increasing the risk of secondary ocular infections, particularly from fungi, viruses (such as herpes simplex), and bacteria. Acute purulent infections of the eye may be masked or exacerbated by corticosteroid medications. Furthermore, the use of tobramycin, an aminoglycoside antibiotic, carries a risk of developing hypersensitivity reactions, including itching, lid edema, and conjunctival erythema. Superinfection with non-susceptible organisms, including fungi, may occur with prolonged use of antibiotics. Discontinuation of the medication is warranted if such reactions or superinfections are suspected or confirmed. Patients should be advised against wearing contact lenses during treatment due to the risk of exacerbating infection or interfering with drug delivery.
- This medication is for ophthalmic use only and should not be injected.
- Patients should be advised not to wear contact lenses during treatment, especially if they have signs and symptoms of ocular infection.
- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.
- Intraocular pressure should be checked routinely.
- The use of corticosteroids may also lead to the suppression of the host immune response and thus increase the likelihood of secondary ocular infections, including fungal, viral (e.
- g.
- , herpes simplex), and bacterial infections.
- Acute purulent infections of the eye may be masked or exacerbated by the presence of corticosteroid medication.
- Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application.
- Superinfection with non-susceptible organisms, including fungi, may occur with prolonged use of antibiotics.
- If superinfection or signs of hypersensitivity develop, discontinue use and institute appropriate therapy.
How it Works (Mechanism of Action)
Loteprednol etabonate + tobramycin combines a corticosteroid and an aminoglycoside antibiotic. Loteprednol etabonate is a 'soft' corticosteroid that primarily exerts its anti-inflammatory effects by inhibiting the release of inflammatory mediators and suppressing the migration of inflammatory cells. It acts by binding to glucocorticoid receptors, modulating gene expression to reduce the production of prostaglandins, leukotrienes, and other cytokines. Its ester structure allows for rapid hydrolysis to inactive metabolites, thereby minimizing systemic side effects. Tobramycin is a broad-spectrum aminoglycoside antibiotic. It acts by binding to the 30S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. This disruption leads to the formation of aberrant proteins, increased bacterial cell membrane permeability, and ultimately bacterial cell death. Tobramycin is effective against a wide range of Gram-negative bacteria (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae) and some Gram-positive bacteria (e.g., Staphylococcus aureus, Staphylococcus epidermidis).